NASDAQ:ZVRA Zevra Therapeutics (ZVRA) Stock Price, News & Analysis $12.02 -0.11 (-0.91%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$12.03 +0.01 (+0.08%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Zevra Therapeutics Stock (NASDAQ:ZVRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zevra Therapeutics alerts:Sign Up Key Stats Today's Range$11.58▼$12.2250-Day Range$8.66▼$12.7952-Week Range$6.19▼$13.16Volume985,927 shsAverage Volume1.11 million shsMarket Capitalization$657.25 millionP/E RatioN/ADividend YieldN/APrice Target$23.71Consensus RatingBuy Company Overview Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. Read More Zevra Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreZVRA MarketRank™: Zevra Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 660th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingZevra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZevra Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Zevra Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Zevra Therapeutics are expected to grow in the coming year, from ($1.95) to $0.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zevra Therapeutics is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zevra Therapeutics is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZevra Therapeutics has a P/B Ratio of 16.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Zevra Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.07% of the float of Zevra Therapeutics has been sold short.Short Interest Ratio / Days to CoverZevra Therapeutics has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Zevra Therapeutics has recently increased by 166.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZevra Therapeutics does not currently pay a dividend.Dividend GrowthZevra Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.07% of the float of Zevra Therapeutics has been sold short.Short Interest Ratio / Days to CoverZevra Therapeutics has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Zevra Therapeutics has recently increased by 166.30%, indicating that investor sentiment is decreasing significantly. News and Social Media3.7 / 5News Sentiment0.71 News SentimentZevra Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Zevra Therapeutics this week, compared to 3 articles on an average week.Search Interest17 people have searched for ZVRA on MarketBeat in the last 30 days. This is an increase of 55% compared to the previous 30 days.MarketBeat Follows10 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zevra Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of Zevra Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 35.03% of the stock of Zevra Therapeutics is held by institutions.Read more about Zevra Therapeutics' insider trading history. Receive ZVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ZVRA Stock News HeadlinesZevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Up 166.3% in JulyAugust 5, 2025 | americanbankingnews.comZevra Therapeutics Announces Details for Q2 2025 Financial Results CallAugust 4, 2025 | globenewswire.comOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast. | InvestorPlace (Ad)Equities Analysts Set Expectations for ZVRA FY2025 EarningsAugust 1, 2025 | americanbankingnews.comQ3 Earnings Forecast for ZVRA Issued By William BlairAugust 1, 2025 | americanbankingnews.comZevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type CJuly 28, 2025 | globenewswire.comZevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)July 18, 2025 | globenewswire.comZevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics ...July 16, 2025 | finanznachrichten.deSee More Headlines ZVRA Stock Analysis - Frequently Asked Questions How have ZVRA shares performed this year? Zevra Therapeutics' stock was trading at $8.34 at the beginning of the year. Since then, ZVRA shares have increased by 44.1% and is now trading at $12.02. How were Zevra Therapeutics' earnings last quarter? Zevra Therapeutics, Inc. (NASDAQ:ZVRA) released its earnings results on Tuesday, May, 13th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.15. The company earned $20.40 million during the quarter, compared to analysts' expectations of $16.96 million. Zevra Therapeutics had a negative trailing twelve-month return on equity of 201.05% and a negative net margin of 226.78%. Read the conference call transcript. Who are Zevra Therapeutics' major shareholders? Zevra Therapeutics' top institutional shareholders include Geode Capital Management LLC (2.27%), AIGH Capital Management LLC (1.68%), Janney Montgomery Scott LLC (0.47%) and Stratos Wealth Partners LTD. (0.40%). Insiders that own company stock include Neil F Mcfarlane, R Laduane Clifton, John B Bode, Joshua Schafer, Thomas Anderson, Matthew R Plooster, Timothy J Sangiovanni, Corey Michael Watton and Tamara A Seymour. View institutional ownership trends. How do I buy shares of Zevra Therapeutics? Shares of ZVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zevra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zevra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Tesla (TSLA). Company Calendar Last Earnings5/13/2025Today8/08/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZVRA CIK1434647 Webwww.kempharm.com Phone(321) 939-3416Fax319-665-2577Employees20Year FoundedN/APrice Target and Rating Average Price Target for Zevra Therapeutics$23.71 High Price Target$29.00 Low Price Target$18.00 Potential Upside/Downside+97.3%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$105.51 million Net Margins-226.78% Pretax Margin-185.88% Return on Equity-201.05% Return on Assets-53.55% Debt Debt-to-Equity Ratio1.46 Current Ratio3.02 Quick Ratio2.93 Sales & Book Value Annual Sales$23.61 million Price / Sales27.84 Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book16.24Miscellaneous Outstanding Shares54,680,000Free Float53,368,000Market Cap$657.25 million OptionableOptionable Beta1.87 10 Stocks Set to Soar in Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:ZVRA) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft....Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.